Nitrogen Containing Hetero Ring Patents (Class 514/43)
  • Patent number: 11116777
    Abstract: Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: September 14, 2021
    Assignee: CITY OF HOPE
    Inventor: Defu Zeng
  • Patent number: 11071747
    Abstract: Certain embodiments of the invention provide a method for breast enhancement in a female mammal (e.g., a human) in need thereof, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to the mammal.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: July 27, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Charles M. Brenner, Po Hien Ear, Ankita Chadda, Amy Sindler, Marie E. Migaud
  • Patent number: 11059848
    Abstract: The present invention relates to artemisinic acid glycoconjugate compounds. More particularly, the present invention relates to a glycoconjugate compound of formula (I) and a process for the preparation of artemisinic acid glycoconjugate compound of formula (I) by using 1,3-dipolar cycloaddition chemistry starting from artemisinic acid.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 13, 2021
    Inventors: Asish Kumar Bhattacharya, Tharun Kumar Kotammagari, Manas Kumar Santra
  • Patent number: 11052100
    Abstract: A nicotinamide riboside composition and preparation method thereof, the icotinamide riboside composition comprises nicotinamide riboside and/or a salt thereof and konjac glucomannan or rebaudioside A. The nicotinamide riboside composition provided by the present invention, used to increase the concentration of NAD in cells, thereby preventing and improving various unhealthy conditions caused by NAD deficiency. is stable in property and easy to store and transport.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 6, 2021
    Assignees: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD, BONTAC INVITROLIFE BIO-TECHNOLOGY (SHENZHEN) CO., LTD, JIANGXI BONZYMES BIOTECHNOLOGY CO., LTD.
    Inventors: Rongzhao Fu, Zhenwei Li, Xinglin Guo
  • Patent number: 11033567
    Abstract: This invention is directed to compositions for promoting wound healing and regeneration and methods of use thereof. In one aspect, methods for promoting wound healing in a subject are provided, the methods comprising: administering a therapeutically effective amount of a DNA methyl transferase inhibitors (DNMT) to the subject. In another aspect, methods for reducing scarring during healing of a skin wound are provided, the methods comprising: administering a therapeutically effective amount of a DNMT inhibitor.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 15, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Cotsarelis, Jen-Chih Hsieh, Ying Zheng
  • Patent number: 11029317
    Abstract: Provided herein are methods, compositions, and kits for diagnosing allograft rejection of organ transplants by identifying the presence of anti-endothelial cell antibodies. Such methods and compositions are independent of external confounders such as recipient age, transplant center, assay, cause of end-stage disease, co-morbidities, immunosuppression usage, and the like.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: June 8, 2021
    Assignees: The Johns Hopkins University, Immucor GTI Diagnostics, Inc.
    Inventors: Minnie M. Sarwal, Tara Sigdel, Annette M. Jackson
  • Patent number: 11013733
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 25, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • Patent number: 10874702
    Abstract: The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 29, 2020
    Assignee: PROCARE HEALTH IBERIA, S.L.
    Inventors: Fernando Losa Dominguez, Santiago Palacios, Yann Gaslain
  • Patent number: 10844379
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10821123
    Abstract: A method for treating a human subject having congestive heart failure is disclosed herein. An exemplary method includes orally administering a 10 g to 50 g dose of D-ribose daily to a subject having congestive heart failure, wherein the D-ribose is administered in a single dose after fasting, and the administration of D-ribose is continued over a period of time effective to improve cardiac and/or physical function of the subject.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: November 3, 2020
    Assignee: Bioenergy Life Science, Inc.
    Inventors: Jeffrey A. Thompson, Raj Khankari
  • Patent number: 10815264
    Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 27, 2020
    Assignee: Southern Research Institute
    Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Christophe C. Parsy
  • Patent number: 10780104
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 22, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 10744148
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 18, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 10744120
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 18, 2020
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Patent number: 10624918
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 21, 2020
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow, Radhakrishnan Pillai
  • Patent number: 10603334
    Abstract: Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 31, 2020
    Assignee: NewSouth Innovation Pty. Limited
    Inventors: Lindsay Edward Wu, David A. Sinclair
  • Patent number: 10570169
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: February 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
  • Patent number: 10513706
    Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 24, 2019
    Assignee: The Scripps Research Institute
    Inventors: Floyd E. Romesberg, Denis A. Malyshev
  • Patent number: 10487061
    Abstract: The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 26, 2019
    Assignee: Chimerix, Inc.
    Inventors: Roy Wendell Ware, Aaron Leigh Downey
  • Patent number: 10485813
    Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 26, 2019
    Assignee: Shire ViroPharma Incorporated
    Inventor: John D. Peabody, III
  • Patent number: 10426769
    Abstract: The present invention is based on the fact that imiquimod, which is a substance that enhances Toll-like receptor 7 (TLR7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein the TLR7 agonist used for the immune system disease inhibits fatty acid synthetase (FAS), activates autophagosome or inhibits IGF-1.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 1, 2019
    Assignees: KNOTUS CO., LTD., KNOTUS LIFE SCIENCE INC.
    Inventors: Do Hyeong Kim, Sok Ho Kim, Jung Kee Kwon
  • Patent number: 10357516
    Abstract: The present invention provides pathogen-inactivated red blood cell compositions.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: July 23, 2019
    Assignee: Cerus Corporation
    Inventors: Naheed Mufti, Anna Erickson, Anne North
  • Patent number: 10344046
    Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 9, 2019
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 10251903
    Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 9, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
  • Patent number: 10238678
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: March 26, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Patent number: 10239912
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Patent number: 10179144
    Abstract: The present disclosure describes various formulations and compositions for improving one's vitality and health. The formulations may be particularly useful for treating or alleviating at least erectile dysfunction, increasing muscle mass, and encouraging saliva and tear production. In one example such a composition may include 1-methylfolate, methylcobalamin, n-acetylcysteine, pterostilbene, and nicotinamide riboside.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 15, 2019
    Inventor: Roger F. Duronio
  • Patent number: 10160750
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: December 25, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Donald J. P. Pinto, James R. Corte, William R. Ewing
  • Patent number: 10076534
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 18, 2018
    Assignee: University of South Florida
    Inventor: Jin Q. Cheng
  • Patent number: 10072262
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 11, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Patent number: 10058507
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 28, 2018
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
  • Patent number: 10047114
    Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 14, 2018
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 9861651
    Abstract: The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 9, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Kevin Brown, Anthony Sauve, Samie Jaffrey
  • Patent number: 9849116
    Abstract: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: December 26, 2017
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Valentin Gribkoff, Thomas Petzinger, Jr.
  • Patent number: 9828408
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 28, 2017
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9821173
    Abstract: An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 21, 2017
    Assignee: Case Western Reserve University
    Inventor: Anthony J. Berdis
  • Patent number: 9815864
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same, of the Formula (I). Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 14, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Jerome Deval, Zhinan Jin
  • Patent number: 9784728
    Abstract: The present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein: a. the membrane localization peptide is located at the N-terminus of the fluorescent fusion polypeptide and is physically bound, optionally through a linker, to the fluorescent peptide, which in turn is physically bound, optionally through a linker, to the second messenger transduction protein binding peptide; and b. the second messenger transduction protein binding peptide is physically bound, optionally through a linker, to the reticulum retention signal, which in turn is located at the C-terminus of the fluorescent fusion polypeptide.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: October 10, 2017
    Assignee: INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS S.L.
    Inventors: Danel Kortazar Zabala, Aida Clarisa Salado Pogonza, Jorge Gámiz Mata, Meritxell Roura Ferrer, Rosa Mella López, Patricia Villacé Lozano
  • Patent number: 9757596
    Abstract: The present invention relates to a composition comprising at least 3 different diols, wherein said diols have the general structure (CH2)nH2O2, wherein n is the number of CH2 and being between 3 to 10, in a total amount of from about 0.1 to about 50% (v/v), a method for producing the composition and its use, such as in therapy. The composition may be a pharmaceutical, cosmetic, antimicrobial or preservative composition. The composition is useful in inactivating microorganisms or preventing their growth.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: September 12, 2017
    Assignee: AMBRIA DERMATOLOGY AB
    Inventors: Jan Faergemann, Thomas Hedner
  • Patent number: 9718851
    Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R4, R5a, R5b, Rb5, Rb6 and D are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 1, 2017
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Bin Wang, Guoqiang Wang, Yat Sun Or
  • Patent number: 9670238
    Abstract: The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R1 and R2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2?-deoxy-5-azacytidine) used in clinic for treating myeloma.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 6, 2017
    Assignee: Ohara Pharmaceutical Co., Ltd.
    Inventors: Magoichi Sako, Xiong Luo
  • Patent number: 9655914
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 23, 2017
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 9598457
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 21, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: David Bernard Smith, Leonid Beigelman, Guangyi Wang, Michael Hunter Welch
  • Patent number: 9556216
    Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are as defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: January 31, 2017
    Assignee: Novartis AG
    Inventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
  • Patent number: 9539274
    Abstract: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 10, 2017
    Assignee: Pericor Therapeutics, Inc.
    Inventor: Dennis T. Mangano
  • Patent number: 9526742
    Abstract: A pharmaceutical composition including at least one epigenome-modifying compound, for a use thereof in the treatment of genetic muscular diseases linked to a conformational disorder of at least one protein, said disorder causing the cellular degradation of the protein.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: December 27, 2016
    Assignee: GENETHON
    Inventor: Isabelle Richard
  • Patent number: 9518079
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: December 13, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 9498492
    Abstract: This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: November 22, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 9486470
    Abstract: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 8, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 9486492
    Abstract: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 8, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti